{
    "nct_id": "NCT04508725",
    "official_title": "Early Therapeutic Monitoring of Response to Therapy With Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)",
    "inclusion_criteria": "* 18 years of age or older\n* Pathology-confirmed diagnosis of metastatic RCC\n* At least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound imaging\n* Written informed consent.\n\nSpecific inclusion criteria:\n\n* arm 1: planned to be treated with combination of VEGFR2 tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)\n* arm 2: planned to be treated with non-ICI therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "-Any comorbid condition that, in the opinion of the treating provider or the Protocol Directors, compromises the participant's ability to participate in the study",
    "miscellaneous_criteria": ""
}